Heritability of Metoprolol and Torsemide Pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 6, 2015, Pages 611-621

  Matthaei, J ^a   Brockmeoller, J ^a   Tzvetkov, M V ^a   Sehrt, D ^a   Sachse Seeboth, C ^a   Hjelmborg, J B ^b   Moller, S ^b   Halekoh, U ^b   Hofmann, U ^c   Schwab, M ^c,d   Kerb, R ^c  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; METOPROLOL; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TORASEMIDE; CYP2C9 PROTEIN, HUMAN; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; SULFONAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; DIZYGOTIC TWINS; EUROPEAN; FEMALE; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HEADACHE; HERITABILITY; HUMAN; HUMAN EXPERIMENT; MALE; MONOZYGOTIC TWINS; NAUSEA; NORMAL HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SINUS BRADYCARDIA; STRUCTURAL EQUATION MODELING; TURKISH CITIZEN; ADOLESCENT; BIOTRANSFORMATION; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; HEREDITY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHENOTYPE; TWINS; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HEREDITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METOPROLOL; MIDDLE AGED; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; SULFONAMIDES; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 84954326746     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.258     Document Type: Article

References (51)

1. Spear, B.B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001).
2. Kongkaew, C., Noyce, P.R. & Ashcroft, D.M. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann. Pharmacother. 42, 1017-1025 (2008).
3. Evans, W.E. & McLeod, H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
4. Blake, C.M., Kharasch, E.D., Schwab, M. & Nagele, P. A metaanalysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin. Pharmacol. Ther. 94, 394-399 (2013).
5. Vormfelde, S.V. et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin. Pharmacol. Ther. 76, 557-566 (2004).
6. Vormfelde, S.V., Toliat, M.R., Schirmer, M., Meineke, I., Nurnberg, P. & Brockmoller, J. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele∗3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 83, 815-817 (2008).
7. Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedeberg Arch Pharmacol. 369, 23-37 (2004).
8. Zanger, U.M. et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585 (2001).
9. Daly, A.K. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch. Toxicol. 87, 407-420 (2013).
10. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. 5, 6-13 (2005).
11. Holstein, A., Beil, W. & Kovacs, P. CYP2C metabolism of oral antidiabetic drugs-impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug Metab. Toxicol. 8, 1549-1563 (2012).
12. Goldstein, J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355 (2001).
13. Sim, S.C., Kacevska, M. & Ingelman-Sundberg, M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenom. J. 13, 1-11 (2013).
14. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157-181 (2011).
15. Mahgoub, A., Idle, J.R., Dring, L.G., Lancaster, R. & Smith, R.L. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2, 584-586 (1977).
16. Griese, E.U. et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8, 15-26 (1998).
17. Sachse, C., Brockmoller, J., Hildebrand, M., Muller, K. & Roots, I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 8, 181-185 (1998).
18. Sehrt, D., Meineke, I., Tzvetkov, M., Gultepe, S. & Brockmoller, J. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 12, 783-795 (2011).
19. Nies, A.T. et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5, 1 (2013).
20. Alexanderson, B., Evans, D.A. & Sjoqvist, F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br. Med. J. 4, 764-768 (1969).
21. Vesell, E.S. & Page, J.G. Genetic control of drug levels in man: phenylbutazone. Science 159, 1479-1480 (1968).
22. Vesell, E.S. & Page, J.G. Genetic control of dicumarol levels in man. J. Clin. Invest. 47, 2657-2663 (1968).
23. Scott, J. & Poffenbarger, P.L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28, 41-51 (1979).
24. Stage, T.B. et al. A twin study of the trough plasma steady-state concentration of metformin. Pharmacogenet. Genom. 25, 259-262 (2015).
25. Boomsma, D., Busjahn, A. & Peltonen, L. Classical twin studies and beyond. Nat. Rev. Genet. 3, 872-882 (2002).
26. Martin, N., Boomsma, D. & Machin, G. A twin-pronged attack on complex traits. Nat. Genet. 17, 387-392 (1997).
27. Vesell, E.S. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol. Ther. 41, 535-552 (1989).
28. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283-289 (1998).
29. Kalow, W., Endrenyi, L. & Tang, B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 58, 281-284 (1999).
30. Regardh, C.G., Jordo, L., Ervik, M., Lundborg, P., Olsson, R. & Ronn, O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin. Pharmacokinet. 6, 375-388 (1981).
31. Regardh, C.G. et al. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur. J. Clin. Pharmacol. 24, 221-226 (1983).
32. Spahn, H., Knauf, H. & Mutschler, E. Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. Eur. J. Clin. Pharmacol. 39, 345-348 (1990).
33. Schwartz, S., Brater, D.C., Pound, D., Green, P.K., Kramer, W.G. & Rudy, D. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin. Pharmacol. Ther. 54, 90-97 (1993).
34. Gasso, P. et al. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. Pharmacogenomics 14, 1551-1563 (2013).
35. Verhoef, T.I., Redekop, W.K., Daly, A.K., van Schie, R.M., de Boer, A. & Maitland-van der Zee, A.H. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br. J. Clin. Pharmacol. 77, 626-641 (2014).
36. Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
37. Ozdemir, V. et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
38. Rijsdijk, F.V. & Sham, P.C. Analytic approaches to twin data using structural equation models. Brief. Bioinform. 3, 119-133 (2002).
39. Rasmussen, B.B., Brix, T.H., Kyvik, K.O. & Brosen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12, 473-478 (2002).
40. Martin, N.G., Eaves, L.J., Kearsey, M.J. & Davies, P. The power of the classical twin study. Heredity 40, 97-116 (1978).
41. Neale, M.C., Eaves, L.J. & Kendler, K.S. The power of the classical twin study to resolve variation in threshold traits. Behav. Genet. 24, 239-258 (1994).
42. Chambers, G.M. et al. Hospital costs of multiple-birth and singleton-birth children during the first 5 years of life and the role of assisted reproductive technology. JAMA Pediatr. 168, 1045-1053 (2014).
43. Bouchard, T.J., Jr., Lykken, D.T., McGue, M., Segal, N.L. & Tellegen, A. Sources of human psychological differences: the Minnesota Study of Twins Reared Apart. Science 250, 223-228 (1990).
44. Steimer, W. et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50, 1623-1633 (2004).
45. Kirchheiner, J. et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312 (2004).
46. Snijders, T.A.B. & Bosker, R.J. Modeled variance in 2-level models. Sociol. Method. Res. 22, 342-363 (1994).
47. Sham, P.C. Statistics in Human Genetics (John Wiley & Sons, Hoboken, NJ, 1998).
48. Holst, K. & Scheike, T. Mets: analysis of multivariate event times, R package version 1.1.1. (2015). http://CRAN.R-project.org/package5mets
49. R-Core-Team. R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria, (2015). http://www.R-project.org
50. Mcculloch, C.E., Shayle, R. & Neuhaus, J.M. Generalized, Linear, and Mixed Models, 2nd edn. (John Wiley & Sons, Hoboken, NJ, 2008).
51. Bates, D., Maechler, M., Bolker, B. & Walker, S. lme4: Linear mixed-effects models using Eigen and S4, R package version 1.1-7. (2014).